"Belgium Pharmaceuticals & Healthcare Report Q1 2015" now available at Fast Market Research

Belgium boasts a fair and transparent regulatory regime which, in addition to a progressive business environment, has been instrumental in retaining the country's appeal as a strategic regional hub for multinational drugmakers. Notwithstanding a particularly sluggish recovery from the e urozone crisis, per capita pharmaceutical expenditure remain s markedly above the regional average and widespread access to healthcare will continue to support already high demand for treatments . While fiscal pressures threaten the sustainability of this system, i n the short term, measures to contain drug prices and restrain public spending will be softened by the constitutional obligation to provide access to high quality health services. Over the long term, however , with policy decisions in Belgium relying on consensus among a host of fragmented stakeholders and public agencies, drugmakers will find the direction of future regulation particularly difficult to discern.

Full Report Details at
- http://www.fastmr.com/prod/938353_belgium_pharmaceuticals_healthcare_report_q1_2015.aspx?afid=301

Headline Expenditure Projections

* Pharmaceuticals: From EUR5.78bn (USD7.19bn) in 2014 to EUR5.79bn (USD7.20bn) in 2015; -0.04% in local currency terms and -6.7% in US dollar terms. Local currency forecast above Q414.
* Healthcare: From EUR42.75bn (USD53.22bn) to EUR43.85bn (US54.59bn) 2015; +2.6% in local currency terms and -4.3% in US dollar terms. Local currency forecast above Q414 .

Risk/Reward Rating:

In our Q115 Pharmaceutical Risk/Reward Index Belgium remains ranked sixth out of the fifteen markets surveyed in the Western European region. Despite average reward scores, Belgium is markedly outperformed by the growth potential of markets such as the UK and Germany.

Key Trends and Developments

* Belgian drugmaker UCB in November 2014 entered an agreement with private equity groups Advent International and Avista Capital Partners to divest its US-based specialty generics business Kremers Urban. Subject to regulatory approval and other customary closing conditions, UCB will receive...

The Belgium Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Belgium Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Belgian pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Belgium to test other views - a key input for successful budgeting and strategic business planning in the Belgian pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- Peru Pharmaceuticals & Healthcare Report Q1 2015
- Lebanon Pharmaceuticals & Healthcare Report Q1 2015
- Turkey Pharmaceuticals & Healthcare Report Q1 2015
- India Pharmaceuticals & Healthcare Report Q1 2015
- Slovenia Pharmaceuticals & Healthcare Report Q1 2015